It would appear that a new treatment that is effective in heavily pre-treated patients may be on the near-term horizon. Dr. Sartor is the lead author of a New England Journal of Medicine (NEJM) article published June 23, 2021 that demonstrates that PSMA-617 Lu-177 prolongs survival in patients with metastatic prostate cancer. These patients had undergone multiple therapies including conventional and novel hormones and chemotherapy, yet still had disease progression. PSMA-617 Lu-177 is a “smart bomb” that delivers radiation precisely to the region of the tumor.
PSMA is a protein expressed on prostate cancer cells and Lu-177 is an isotope that radiates the area around PSMA-expressing cells. This therapy had been used in smaller trials but the NEJM manuscript describes experiences in a large randomized trial (VISION). Given the positive nature of the treatment in prolonging survival in heavily pre-treated patients, it is anticipated that the FDA will give approval for this therapy. Further trials are not being conducted in less heavily pretreated patients.
To read more on the article click here.